Dublin City University and pharmaceutical company Wyeth have announced a four-year research project in the production of biopharmaceuticals. The research project will receive €4m from Science Foundation Ireland (SFI).
The research will be performed at the National Institute for Cellular Biotechnology (NICB) at DCU in collaboration with Wyeth scientists at Wyeth BioPharma Campuses in Clondalkin in Dublin and Andover, Massachusetts.
The Wyeth campus in Clondalkin is now in commercial production and employs more than 1,000 people.
A statement said Wyeth's commitment to the project would be 'comparable' to that contributed by SFI.
Biopharmaceuticals are drugs produced using living cells as an essential part of the manufacturing process. This new research is intended to facilitate breakthroughs in therapeutic proteins, which have improved the treatment of diseases such as rheumatoid arthritis, multiple sclerosis and diabetes.
